After being told he might not walk for two years, the longtime Little League football coach fought through treatment to ...

Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatment Japanese Ministry of Health, Labour and Welfare decision adds to similar ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...

VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for ...

Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase-qvfc) is a prescription medicine that is used to treat certain muscle and nerve conditions. It is a combination of two medicines, efgartigimod alfa and ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI. CIDP ...

CIDP treatment focuses on reducing and slowing the immune processes damaging your peripheral nervous system. It includes corticosteroids, intravenous immunoglobulin, and plasma exchange, but new ...

CIDP is a treatable condition that affects the peripheral nervous system. IVIG, plasma exchange, and corticosteroid therapy are the first-line treatment options, but a newer medication for adults has ...